Print this page
-
A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma.
Protocol: 011909Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
The Prophylactic Use of Loratadine for Granulocyte-Colony Stimulating Factor (G-CSF) Induced Bone Pain in Multiple Myeloma Patients Undergoing Stem Cell Mobilization.
Protocol: 011910Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Bones and Joints
Ill-Defined Sites
Multiple Myeloma -
Prospective Multicenter Observational Study of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Starting Second- or Third-line Therapy and not Receiving Autologous Stem Cell Transplant.
Protocol: 012104Principal Investigator:
- Andrew Evens
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase Ib, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Efficacy Of Subcutaneous Glofitamab Following Obinutuzumab Pretreatment in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma.
Protocol: 012107Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Machine Learning-based High-throughput and Integrative Immunological Synapse Quality Evaluation As a Composite Biomarker for Predicting CAR Therapy Efficacy in Immuno-Oncology.
Protocol: 012108Principal Investigator:
- Yun Kyoung Tiger
Applicable Disease Sites: Hodgkin's Lymphoma
Multiple Myeloma
Non-Hodgkin's Lymphoma -
Study Protocol Cancer in Pregnancy (CIP-study)
Protocol: 012201Principal Investigator:
- Andrew Evens
Applicable Disease Sites: Any Site
Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma -
Fitness-Adapted, Pembrolizumab-Based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above.
Protocol: 012203Principal Investigator:
- Andrew Evens
Applicable Disease Sites: Hodgkin's Lymphoma -
A Long-Term Study for Participants Previously Treated With Ciltacabtagene Autoleucel.
Protocol: 012204Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Multiple Myeloma -
Antibodies to Commensal Bacteria in Lymphoma Pathogenesis
Protocol: 012209Principal Investigator:
- Yun Kyoung Tiger
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma.
Protocol: 012302Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 1 Study to Assess Safety and Tolerability of REGN5837, an Anti-CD22 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination with Odronextamab, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with Aggressive B-Cell Non-Hodgkin Lymphomas (ATHENA-1)
Protocol: 012303Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Phase II Study to Assess the Efficacy of Combined Tafasitamab and Rituximab in Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder.
Protocol: 012306Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Phase 1/2 Study of Linvoseltamab (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Previously Untreated Patients with Symptomatic Multiple Myeloma (Linker-MM4 Study).
Protocol: 012310Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
Phase 1/Expansion Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma.
Protocol: 012312Principal Investigator:
- Yun Kyoung Tiger
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study.
Protocol: 012314Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Lymphoid Leukemia -
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
Protocol: 012316Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin's Lymphoma